Anthracycline extravasation injuries: management with dexrazoxane | Zendy

Karin Jordan | Zendy; Behlendorf | Zendy; Mueller | Zendy; HansJoachim Schmoll | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anthracycline extravasation injuries: management with dexrazoxane

Author(s) -

Karin Jordan,

Behlendorf,

Mueller,

HansJoachim Schmoll

Publication year - 2009

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.s3694

Subject(s) - dexrazoxane , medicine , extravasation , anthracycline , antidote , chemotherapy , surgery , toxicity , pathology , cancer , breast cancer

The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research